Dubé) has obtained GWAS on clinical trial data for glycaemic response and cardiovascular outcomes for the novel type 2 diabetes drug classes GLP-1RAs, SGLT2 inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors, and should report in the next 12 months (see https://gtr.ukri.org/projects?ref=MR%2FT032014%2F1). This evidence concerns the gene DPP4 and type 2 diabetes mellitus.